right btr, and your question about why someone here blamed Denner for 14 to 8 (even though it was BS' tweet that took it down) but did not credit Denner with 8 to 14 is valid and has gone unanswered. Everything this company is looking forward to in the months to come is predicated on the company being on a sound financial footing. Thanks to Denner's brilliant series of expense reducing, revenue producing decisions we now enjoy a very comfortable balance sheet and begin 2017 in a position of strength from which we see the sp continue to ascend as we near term catalysts. Again, once we achieve the Brigatinib approval and that uncertainty is resolved, our value to BP will be much greater than now. Barring some unforeseen disaster (and we have had more than our share) the sp should continue to rise with more good news expected for both Ponatinib and 788 in 2017. Having said that, unknown risks are always there both internally and externally which is why I would prefer a buyout sooner rather than later, realizing that by doing so we are probably forfeiting additional millions in personal profits. So be it, I learned my lesson in 2013. 26-31 is fine now, at least for me. But if we wait, I am sure 40 plus will be realized. Not a terrible predicament and worth the 3 year wait for this rebound.
AI
